Full Press Release Details
Pharma to Presents Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International
Calicivirus Conference
Wash. (July 10, 2025) - Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor
CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11,
2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company's President and co-CEO, will present "Oral Direct-Acting Antiviral
CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results" on September 11.
year's Calicivirus Conference will bring together the world's leading norovirus experts, making it the ideal venue to share
our pan-viral protease inhibitor CDI-988 Phase 1 data and clinical development strategy," said Dr. Lee. "Norovirus causes
a highly contagious gastrointestinal illness, triggering severe vomiting and diarrhea, and has a substantial economic impact with a societal
cost of approximately $60 billion each year globally according to the CDC. There is no approved vaccine or antiviral therapeutics
for norovirus infection. We are encouraged by our molecule's novel pan-viral activity against all noroviruses including GII.4 and
was designed and developed with Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor to a
highly conserved region in the active site of 3CL viral proteases. Based on a novel mechanism
of action and superior broad-spectrum antiviral activity, CDI-988 represents a compelling first-in-class oral treatment for noroviruses,
which are members of the calicivirus family, and for coronaviruses. Cocrystal has completed a single-center,
randomized, double-blind, placebo-controlled Phase 1 study in healthy adults evaluating the safety, tolerability and pharmacokinetics
of CDI-988, including a food effect cohort.
proprietary structural biology, along with its expertise in enzymology and medicinal chemistry, enable its development of novel antiviral
agents. The Company's platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, providing
immediate insight to guide structure activity relationships. This helps to identify novel binding sites and allows for a rapid turnaround
of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate
the development of best-in-class antiviral therapies that have fast onset of action or shortened treatment time, are safe, well tolerated
and easy to administer, and are effective against all viral subtypes that cause disease and have a high barrier to viral resistance.
the Calicivirus Conference
International Calicivirus Conference is held every three years and unites scientists from across the globe who study calicivirus
virology, evolution, pathogenesis, structural biology, diagnosis, epidemiology, treatment and prevention. The conference aims to foster
open discussions, spark new collaborations and explore groundbreaking research. Delegates have the opportunity to engage with the latest
advances in the field through state-of-the-art lectures, oral presentations and poster sessions.
Cocrystal Pharma, Inc.
Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication
process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Note Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the potential for the Company's CDI-988 product candidate as a treatment for norovirus. The words "believe,"
"may," "estimate," "continue," "anticipate," "intend," "should,"
"plan," "could," "target," "potential," "is likely," "will,"
"expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated
by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking
statements include, but are not limited to, our need for additional capital to fund our operations
over the next 12 months, risks relating to our ability to obtain regulatory approval for
and proceed with clinical trials including recruiting volunteers and procuring materials for such studies by our clinical research organizations
and vendors, the results of such studies, our and our collaboration partners' technology and software performing as expected, general
risks arising from clinical studies, regulatory changes, and potential development of effective treatments and/or vaccines by competitors,
potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, the
impact of the Trump Administration's policies and actions on regulation affecting the FDA and other healthcare agencies and potential
staffing issues resulting therefrom, as well as other government actions such as tariffs which may cause delays or force us to incur
additional costs to proceed without development programs. Further information on our risk factors is contained in our filings
with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from
time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by law.